Linda Borgonovo

Beyond eosinophil depletion: long-term clinical trajectory and durability of response to benralizumab in patients with severe eosinophilic asthma and CRSwNP: an 18-month real-world study (the BANDOR study)

Background The management of patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps requires therapies capable of inducing stable remission. While benralizumab is an established treatment for severe asthma, randomized controlled trials in nasal poly...